Aldosterone Antagonist Drug Class List

Drugs in Drug Class: Aldosterone Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	ALDACTONE	spironolactone	TABLET;ORAL	012151-010	Dec 30, 1983	AB	RX	Yes	Yes
Pfizer	ALDACTONE	spironolactone	TABLET;ORAL	012151-009	Dec 30, 1983	AB	RX	Yes	No
Pfizer	ALDACTONE	spironolactone	TABLET;ORAL	012151-008	Dec 30, 1982	AB	RX	Yes	No
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	9,757,394		Y
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	11,395,828

Aldosterone Antagonist Patent Landscape and Market Dynamics (Key Patents, Exclusivity Timelines, Generic/Biosimilar Risk, and Competitive Outlook)

Last updated: July 29, 2026

Aldosterone antagonists in clinical use cluster around two active ingredients: spironolactone (small molecule, older, off-patent), and the more selective mineralocorticoid receptor antagonists (MRAs) eplerenone and finerenone. The near-term patent and market-risk picture is driven by (1) method-of-use and formulation patents for eplerenone and finerenone, (2) combination-product exclusivities where present, and (3) regulatory exclusivity tied to label expansions that can delay generic substitution even when foundational compositions are expired. In practice, the biggest “litigation and entry” pressure points are Orange Book-listed exclusivities and patents for finerenone and newer label indications, while spironolactone largely acts as a low-cost, generic anchor.

What patents protect aldosterone antagonists like eplerenone and finerenone in the Orange Book?

Short answer: Protection is typically split across composition-of-matter (often expired for older drugs), plus durable secondary IP around (a) specific patient subpopulations and outcomes, (b) dose-ranging and titration regimens, (c) formulation/manufacturing details, and (d) specific combinations. For finerenone, the estate most relevant to generic timing usually sits in method-of-use and label-linked patents rather than composition-only claims.

Which active ingredients define the aldosterone antagonist patent estate?

• Spironolactone: older, widely generic, limited remaining patent leverage in most markets; competitive pricing compresses returns.
• Eplerenone: generally earlier-generation composition IP; remaining value is typically from secondary patents tied to specific indications or regimen concepts.
• Finerenone: newer; strongest patent-centered market protections align with modern chronic disease indications (including cardiometabolic and kidney disease label expansions) and entrenched dosing patterns.

How many patents typically cover an aldosterone antagonist launch or label expansion?

In MRAs, the “coverage count” is usually dominated by:

• Method-of-use patents (indication-specific or subgroup-specific).
• Formulation patents (tablet composition, coating, stability, particle engineering).
• Combination patents (fixed-dose or regimen patents).
• Manufacturing/process patents (less frequent for entry-blocking but can drive design-around work).

For finerenone and modern-label MRAs, the practical number of Orange Book-listed patents that matter for entry is the subset that are (1) tied to an FDA-approved product and (2) not already expired or carved out by licensing/settlement.

What claim types drive generic entry risk for aldosterone antagonists?

Generic entry risk concentrates where the generic must prove non-infringement or invalidity for patents that track:

• Clinical outcome-defined indications (for example, reduction of specific adverse endpoints).
• Dose and titration algorithms (when label or approved regimen is narrow).
• Renal function-based dosing rules (where specific eGFR thresholds or potassium management windows appear in claims).
• Combination regimens with background standards of care when claims are drafted to regimen steps rather than just the combination ingredients.

---

When does aldosterone antagonist exclusivity expire and when can generics launch?

Short answer: Launch timing is governed by a combination of (1) patent expirations (composition and method-of-use) and (2) non-patent FDA exclusivities (new chemical entity, new clinical investigation, and pediatric exclusivity) that attach to specific NDA/BLA approvals and label supplements. For MRAs, the key driver is that label expansions can extend market exclusivity through patent term adjustments and application of pediatric or additional exclusivity, even when the base compound is older.

What exclusivity types matter for aldosterone antagonists?

• New Chemical Entity (NCE) / 5-year style exclusivity: applies to the first approval of a compound, not the later label. Finerenone is the relevant modern MRA for this category; spironolactone is not.
• New clinical investigation (NCI) / 3-year style exclusivity: attaches to new trials supporting label changes and can delay approval of an ANDA that relies on the same reference listed drug.
• 5-year Orphan (rare in this class): not a typical MRA pathway.
• Patent Term Adjustment (PTA): can push out listed patent expiration dates.
• Pediatric exclusivity (6 months): can extend the time for exclusivity-linked patents.

How do you convert exclusivity to a generic launch window?

A practical framework:

1. Identify the latest FDA approval that created/updated exclusivity-linked protections for a given finerenone strength or dosage form.
2. Identify the Orange Book-listed patents covering that approved product and indication.
3. Determine which patents are earliest to expire and whether any are protected by injunctions via active litigation.
4. For ANDA applicants, assess whether a Paragraph IV route can avoid the remaining patents or whether a carve-out settlement exists.

---

What Paragraph IV (ANDA) challenges exist for aldosterone antagonists?

Short answer: The most litigation-relevant Paragraph IV activity typically clusters around finerenone and other MRAs with the highest remaining patent density and market size. Spironolactone generics largely face no meaningful Paragraph IV gate because competition is already entrenched.

What do Paragraph IV challenges usually target in aldosterone antagonists?

Common strategies:

• Patent invalidity challenges to method-of-use patents tied to outcomes.
• Non-infringement by changing:
  • dosing schedule,
  • patient inclusion,
  • or potassium management steps, while still meeting label requirements through generic design and wording.
• Design-around for formulation/manufacturing patents if the claim scope is process-specific.

What settlement structures most often impact aldosterone antagonist entry?

Typical outcomes in this category:

• Sublicense or authorization tied to specific product attributes.
• Delayed launch or shared-entry schedules.
• Carve-out where the generic is allowed for some strengths or indications but not others.

---

What is the Orange Book status of finerenone and other aldosterone antagonists?

Short answer: The Orange Book status is the authoritative map for:

• which patents are listed for the finerenone NDA product by strength/dosage form, and
• what those patents’ expiration dates and exclusivity tie-ins are.

How to interpret Orange Book listings in aldosterone antagonists

For each product and strength, look for:

• Active patents and whether they expire on different dates.
• Regulatory exclusivities that may delay ANDA approval even when composition claims are expired.
• Linkage to labeling that supports method-of-use infringement theories.

What usually changes the Orange Book landscape over time?

• Label expansions adding new indications.
• Strength or dosage form changes.
• New patent listings with reported tie to approval supplements.

---

How does finerenone’s patent estate compare with eplerenone and spironolactone?

Short answer: Finerenone has the strongest modern patent estate and the highest likelihood of ongoing entry friction for newer labels. Eplerenone is generally further along the value curve with older base IP; remaining protection tends to be secondary. Spironolactone is largely a pricing and supply-led market with minimal patent gating.

Comparative view (patent friction vs competitive intensity)

• Finerenone: higher patent friction; entry timing depends on Orange Book-linked patents and litigation status.
• Eplerenone: moderate friction; fewer active, label-linked barriers relative to finerenone’s current estate.
• Spironolactone: low friction from an IP standpoint; generic substitution is driven by cost and formularies, not patent timing.

Competitive consequence for formulary strategy

• Higher-IP drugs face slower generic erosion and sustain higher net prices longer.
• Lower-IP drugs see rapid discounting and formulary shifts to generics or therapeutic alternatives.

---

What formulations are protected for aldosterone antagonists and what does that mean for ANDA design-arounds?

Short answer: Formulation and manufacturing patents are common but often less decisive than method-of-use patents, unless the claim scope is narrow and directly tied to product-specific attributes that the ANDA must match.

What formulation IP usually appears in aldosterone antagonists?

• Tablet composition and excipients that affect:
  • dissolution,
  • stability,
  • or taste masking.
• Particle size and manufacturing process details that influence:
  • bioavailability consistency,
  • shelf life,
  • or impurity profiles.
• Coating or release-control approaches when the product uses specialized delivery mechanics.

When do formulation patents actually block entry?

Formulation patents can block entry when:

• the claims require specific composition elements that are hard to substitute without changing bioequivalence-critical attributes, or
• the patent prosecution history constrains design-around arguments.

---

What method-of-use patents block generics for aldosterone antagonists?

Short answer: Method-of-use patents usually drive the most durable blocking position in MRAs because they map onto clinical endpoints and patient-selection rules in labeling.

Typical method-of-use claim scopes for MRAs

• Treating specific disease states with defined MRA dosing.
• Managing electrolytes and potassium thresholds in a manner that is incorporated into claimed steps.
• Using MRAs as part of combination strategies where the method claim requires steps tied to:
  • concomitant therapies,
  • monitoring cadence,
  • or risk management.

How does labeling wording affect infringement risk?

• Narrow label language can increase infringement leverage if generic prescribing is constrained to the same language.
• Broader label language can reduce clean infringement triggers and increase the viability of non-infringement by patient selection or regimen tailoring.

---

What patent litigation affects aldosterone antagonist market entry?

Short answer: Litigation risk is product-and-indication specific. For finerenone, the market-impacting disputes are those tied to Orange Book-listed patents for the approved strengths and indications with the highest commercial penetration. Those disputes determine whether the first generic entrant is blocked until patent expiration or is enabled by settlement.

Where injunction leverage matters most

• When patents are scheduled to expire close to planned ANDA timelines.
• When a court blocks an at-risk launch based on likelihood of infringement.

How settlements typically change litigation outcomes

• A court outcome may be less important than settlement terms that set:
  • launch dates,
  • damages carve-outs,
  • and product-specific design constraints.

---

What FDA regulatory pathways affect competition for aldosterone antagonists?

Short answer: Most generic competition uses ANDA with a reference listed drug pathway, but entry timing hinges on whether patent certifications are at-issue and whether exclusivity blocks approval.

ANDA certification mechanics that matter for MRAs

• Paragraph IV certifications trigger litigation timelines that can delay approval.
• If a generic qualifies for non-patent regulatory approval but faces listed patent barriers, the FDA cannot approve until the barrier is resolved.

Bioequivalence and dosing

For MRAs, consistent plasma exposure is necessary to meet bioequivalence. Differences in:

• formulation dissolution,
• food effects,
• or stability profiles can force ANDAs into additional BE work that interacts with timing and regulatory approval schedules.

---

How strong is the patent estate for finerenone and what does it mean for revenue exposure?

Short answer: For finerenone, the patent estate’s strength translates into sustained revenue protection longer than older MRAs, because method-of-use and label-linked patents delay substitution. Revenue exposure for any entrant is dominated by whether the estate supports a settlement-based delay or an injunction through the remaining expiration stack.

Revenue-exposure drivers to monitor

• Number and earliest expiration of Orange Book patents.
• Whether method-of-use patents are still being asserted in active cases.
• Strength-specific exclusivity: finerenone has multiple strengths; a patent might cover only certain presentations.
• Whether new label expansions are pending that could add fresh exclusivity.

---

Generic entry risks exist for aldosterone antagonists: what scenarios produce the fastest erosion?

Short answer: Fast erosion scenarios are those where (1) the foundational composition claims are expired, (2) method-of-use patents expire or are settled, and (3) no exclusivity prevents ANDA approval. In the MRA class, this most often applies to spironolactone and, to a lesser extent, eplerenone; finerenone typically experiences slower erosion due to the modern secondary IP stack.

Fast-entry scenario mechanics

1. ANDA applicant files Paragraph IV and litigates through a window shorter than the remaining patent stack.
2. Court or settlement enables launch before the last method-of-use patent expiration.
3. No regulatory exclusivity blocks approval of the full label or required patient population.

Slow-entry scenario mechanics

• Settlement sets a delayed launch tied to the last key patent expiration.
• Or injunction blocks the at-risk launch, pushing entry to the next expiration.

---

What commercial dynamics shape the aldosterone antagonist market beyond patents?

Short answer: Pricing, formularies, potassium safety management, and the position of MRAs against competing heart-kidney therapies drive adoption more than patent text alone. However, patents determine the speed at which lower-cost generics can capture formulary share after an entry decision becomes commercially viable.

Adoption friction and managed-care behavior

• Potassium monitoring requirements can affect prescriber behavior and persistence.
• Kidney function stratification can drive individualized dosing and limit “one-size-fits-all” substitution narratives.

Substitution patterns

• Generic switching occurs fastest where:
  • the drug is entrenched in formularies,
  • prescribers accept therapeutic equivalence without concerns about dose or monitoring,
  • and patient populations are stable.

---

Key Takeaways

• Finerenone carries the most consequential patent and exclusivity tail in the aldosterone antagonist class, with protection typically anchored in Orange Book-listed method-of-use and formulation patents that track label-defined dosing and patient selection.
• Eplerenone shows less modern patent leverage than finerenone; remaining barriers are usually secondary and less likely to sustain prolonged monopoly without active label-linked patents.
• Spironolactone is largely a generic-driven market with minimal patent gating; competition is led by pricing and supply rather than litigation timelines.
• Generic entry timing is determined by the interaction of patent expiration stacks and FDA exclusivity tied to label supplements, not by composition status alone.
• Litigation and settlements are the main swing factors that convert remaining patent term into real-world launch dates.

FAQs

1. Which aldosterone antagonist has the highest likelihood of prolonged generic delay due to method-of-use patents?
2. How do strength-specific Orange Book listings for finerenone alter generic launch strategy?
3. Can ANDA applicants circumvent MRA method-of-use patents by changing dosing titration patterns while staying within the label?
4. What exclusivity extensions are most relevant to aldosterone antagonist label expansions and what do they delay?
5. How does potassium monitoring language in labeling influence infringement risk for generic MRAs under method-of-use patents?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-30).
2. U.S. Food and Drug Administration. Drug Approval Reports and Drug Trials Snapshots (Finerenone, Eplerenone, Spironolactone). (Accessed 2026-07-30).
3. U.S. Patent and Trademark Office. Patent term adjustment and related FDA-linked patent timing concepts (background materials). (Accessed 2026-07-30).